Acacia Pharma has developed a late-stage pipeline of product candidates for supportive care based on repurposing existing drugs in new therapeutic indications. The Group’s current product candidates are differentiated from the original marketed drug by using a different delivery method and/or dose that is appropriate for its new therapeutic use. Clinical proof of concept has been demonstrated on all candidates in its pipeline.
Repurposing allows the Group to reference existing safety and pharmacological data on the active ingredients, which may reduce the time required to achieve clinical proof of concept in the new indication and the quantity of data needed for regulatory approval. This in turn lowers development costs and provides a higher probability of success compared to the development of new molecular entities.
Acacia Pharma intends to seek to identify additional new repurposed supportive care product candidates using the same discovery process that delivered the current pipeline, and will also assess opportunities to in-license or acquire complementary product candidates.